Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A116Z9 | ISIN: BMG570071099 | Ticker-Symbol: LUP
Frankfurt
21.11.24
08:10 Uhr
0,312 Euro
+0,002
+0,65 %
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
LUYE PHARMA GROUP LTD Chart 1 Jahr
5-Tage-Chart
LUYE PHARMA GROUP LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,3100,33816:27

Aktuelle News zur LUYE PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.11.LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT - APPROVAL OBTAINED FOR CLASS 1 INNOVATIVE ANTIDEPRESSANT LY03021 FOR CLINICAL TRIALS IN CHINA15
01.11.LUYE PHARMA (02186): OVERSEAS REGULATORY ANNOUNCEMENT5
30.10.LUYE PHARMA (02186): COMPLETION OF THE ISSUE OF US$100,000,000 5.85 PER CENT. CONVERTIBLE BONDS DUE 20254
28.10.LUYE PHARMA (02186): CHANGE OF CLOSING DATE OF THE ISSUE OF US$100,000,000 5.85 PER CENT. CONVERTIBLE BONDS DUE 20255
23.10.LUYE PHARMA (02186): PROPOSED ISSUE OF US$100,000,000 5.85 PER CENT. CONVERTIBLE BONDS DUE 2025 AND US$50,000,000 5.85 PER CENT. CONVERTIBLE BONDS DUE ...14
30.08.Luye Pharma shares see 67% upside potential, Citi lifts target after profitability improvements12
28.08.LUYE PHARMA (02186): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 202421
15.08.LUYE PHARMA (02186): NOTICE OF BOARD MEETING6
LUYE PHARMA Aktie jetzt für 0€ handeln
12.08.LUYE PHARMA (02186): DISCLOSEABLE TRANSACTION - THIRD PARTY INVESTMENT IN SHENZHEN LUYE - COMPLETION OF THE INITIAL INVESTMENT6
05.08.LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT - APPROVAL OBTAINED FOR INITIATING CLINICAL TRIALS FOR INNOVATIVE DUAL TAAR1/5-HT2CR AGONIST (LY03020)2
29.07.FDA approves Luye Pharma's ERZOFRI for schizophrenia2
23.07.LUYE PHARMA (02186): DISCLOSEABLE TRANSACTION THIRD PARTY INVESTMENT IN SHENZHEN LUYE26
04.07.LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT - MIMEIXIN (OXYCODONE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE SUSTAINED-RELEASE TABLETS) APPROVED FOR MARKETING ...4
27.06.LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT - THE MANUFACTURING FACILITY OF PALIPERIDONE PALMITATE EXTENDED-RELEASE INJECTABLE SUSPENSION (LY03010) HAS ...6
20.06.LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT - JINYOUPING (ROTIGOTINE MICROSPHERES FOR INJECTION) APPROVED FOR MARKETING IN CHINA2
11.06.LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT - MEIBIRUI (PALIPERIDONE PALMITATE INJECTION) APPROVED FOR MARKETING IN CHINA2
06.06.LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT - NDA FILED FOR RIVASTIGMINE TWICE WEEKLY TRANSDERMAL PATCH IN JAPAN1
28.05.LUYE PHARMA (02186): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS3
28.05.LUYE PHARMA (02186): NOTIFICATION LETTER AND REQUEST FORM TO REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS2
28.05.LUYE PHARMA (02186): ALTERED MEMORANDUM OF ASSOCIATION AND BYE-LAWS1
Seite:  Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1